CoChat
Sign Up
Cited by 128Hypothalamic control of reproductive hormonesGrowth Hormone and Insulin-like Growth FactorsHormonal and reproductive studies

Treatment with the aromatase inhibitor letrozole during adolescence increases near‐final height in boys with constitutional delay of puberty

Hero, Matti, Wickman, Sanna, Dunkel, Leo·2006·Clinical Endocrinology
DOI 10.1111/j.1365-2265.2006.02499.x
Open this paper in CoChat — free account

Abstract

Summary: Objective We investigated whether inhibition of oestrogen biosynthesis with the aromatase inhibitor, letrozole, during adolescence improves near‐final height in boys with constitutional delay of puberty. Patients and methods Seventeen boys with constitutional delay of puberty were randomized to receive testosterone (T) enanthate (1 mg/kg i.m.) every 4 weeks for 6 months in combination with placebo (Pl, n = 8), or the aromatase inhibitor letrozole (Lz, 2·5 mg/day orally) ( n = 9), for 12 months. After treatment, patients were followed up until near‐final height. Height discrepancy was calculated as near‐final height minus mid‐parental target height. Measurements The primary end point was the difference in near‐final height between the groups treated either with T + Pl or T + Lz. Secondarily, height discrepancy and gain in height standard deviation score (SDS) were analysed in both groups. Results Boys treated with T + Lz reached a higher mean near‐final height than did boys on T + Pl (175·8 vs. 169·1 cm, respectively, P = 0·04). In T + Lz‐treated boys, mean near‐final height did not differ from their mid‐parental target height (175·8 vs. 177·1 cm, P = 0·38), whereas in T + Pl‐treated boys, mean near‐final height was lower than mid‐parental target height (169·1 vs. 173·9 cm, P = 0·007). T + Lz‐treated boys had a greater increment in height SDS over the pretreatment height SDS than T + Pl‐treated boys (+1·4 SDS vs. +0·8 SDS, P = 0·03). Conclusions Our findings indicate that in adolescent boys an increase in adult height can be attained by use of aromatase inhibitors.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2006.02499.x

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pretreatment with aromatase inhibitors was described to lead to positive results of testicular sperm extraction in Klinefelter's syndrome patients with low pretreatment testosterone concentrations.

    “Finally, pretreatment with aromatase inhibitors was described to lead to positive results of testicular sperm extraction in Klinefelter's syndrome patients with low pretreatment testosterone concentrations: men from whose testes spermatozoa were retrieved showed higher posttreatment testosterone levels and testosterone over estradiol ratios compared to men in whom no spermatozoa could be obtained,”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [54]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Hero, M., Wickman, S., & Dunkel, L.
Affiliations
  • Helsinki University Hospital (FI)
  • Kuopio University Hospital (FI)
Corresponding author
Dunkel, Leo
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2006-03-23
Volume
64
Issue
5
Pages
510-513
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1111/j.1365-2265.2006.02499.x
OpenAlex
W1975579760
Cited by
128
References
21
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 8 · 2016: 4 · 2015: 8 · 2014: 7 · 2013: 9 · 2012: 2
FWCI
10.23
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
letrozole, aromatase inhibitors, constitutional delay of growth and puberty, adult height, testosterone enanthate, adolescent boys, height gain
MeSH terms
Letrozole, Adolescent, Body Height, Estradiol, Follicle Stimulating Hormone, Humans, Luteinizing Hormone, Male, Nitriles, Prospective Studies, Puberty, Delayed, Testosterone, Time Factors, Triazoles, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review